Abstract:Mechanical overload can be classified into pressure overload and volume overload, causing concentric and eccentric cardiac hypertrophy, respectively. Here, we aimed to differentiate the load-mediated signaling pathways involved in pressure versus volume overload cardiac hypertrophy. Pressure or volume overload was imposed on C57BL/6J mice by transverse aortic constriction (TAC) or aortic regurgitation (AR), respectively. After surgery (2 wk), left ventricular structure and function were evaluated by echocardiographic, hemodynamic, and histological analyses. Signaling pathways related to hypertrophy, fibrosis, angiogenesis, and apoptosis were studied by histological analysis, RT-PCR, and Western blot analysis. Although mean wall stress was similar in both TAC and AR mice, systolic wall stress was significantly increased in TAC and diastolic wall stress was mainly elevated in AR. TAC or AR induced concentric or eccentric compensated hypertrophy, respectively. TAC was associated with more significant fibrosis and apoptosis, whereas AR was associated with more significant angiogenesis. MAPK kinase family, β-arrestin-2, Akt, and Ca<sup>2+</sup>-related signaling pathways were markedly activated in TAC but mildly upregulated or unchanged in AR. Pressure overload and volume overload induce different phenotypic and molecular adaptations in cardiac hypertrophy. Most load-related signaling pathways assessed in this study predominate in pressure but not volume overload. The stimulus-specific heterogeneity in the signaling pathways requires distinct manipulations for further mechanistic and pharmacological studies. NEW & NOTEWORTHY Using the transverse aortic constriction mouse model and the newly developed aortic regurgitation mouse model, we delineated the prominent differences between concentric and eccentric cardiac hypertrophy on morphological, functional, and molecular levels. Our findings are important for the precise diagnosis and treatment of these two types of cardiac hypertrophy. Listen to this article's corresponding podcast at http://ajpheart.podbean.com/e/chinese-english-language-podcast-on-differential-cardiac-remodeling-in-tac-vs-ar/ .

Toll-like receptors in cardiac hypertrophy

Inhibition of TRPC1 Prevents Cardiac Hypertrophy Via NF-κB Signaling Pathway in Human Pluripotent Stem Cell-Derived Cardiomyocytes.

Toll-like receptors as potential therapeutic targets in cardiac dysfunction

Dectin-1 Acts As a Non-Classical Receptor of Ang II to Induce Cardiac Remodeling.

Toll-Like Receptor 2 Signaling Deficiency in Cardiac Cells Ameliorates Ang II-Induced Cardiac Inflammation and Remodeling

Toll-like Receptors: Therapeutic Potential in Life Threatening Diseases- Cardiac Disorders

Inappropriate Activation of TLR4/NF-B is a Cause of Heart Failure

Inhibitory Molecules in Signal Transduction Pathways of Cardiac Hypertrophy

Innate Immune Cells in Pressure Overload-Induced Cardiac Hypertrophy and Remodeling

Toll-Like Receptor 3 in Cardiovascular Diseases

The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease.

The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease

Toll-Like Receptor 4 Mediates Maladaptive Left Ventricular Remodeling and Impairs Cardiac Function After Myocardial Infarction

Regulatory T Lymphocytes in Myocardial Infarction: A Promising New Therapeutic Target

Mitochondria and NLRP3 inflammasome in cardiac hypertrophy

Role of extracellular signal-regulated kinase 1/2 signaling underlying cardiac hypertrophy

Mechanisms of physiological and pathological cardiac hypertrophy

Differential cardiac hypertrophy and signaling pathways in pressure versus volume overload.

Cellular signal transduction in cardiac hypertrophy

Toll-Interacting Protein (Tollip) Negatively Regulates Pressure Overload-Induced Ventricular Hypertrophy In Mice

Transforming growth factor-β and bone morphogenetic protein signaling pathways in pathological cardiac hypertrophy